A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

NCT01834651 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Edwin Posadas, MD